Review of: "A Narrative Review on the Management of Severe COVID-19 Infection Using Stem Cell-based therapies with a Focus on the Registered Clinical Trials"

Alessandro A. Viansone[1]

1 Institut Gustave Roussy

Potential competing interests: No potential competing interests to declare.

This scientific article presents a comprehensive narrative review focusing on the management of severe COVID-19 infection through the utilization of stem cell-based therapies. Amid the global pandemic, there has been a pressing need for innovative and effective treatment modalities, and this review delves into the potential of stem cell therapy in addressing severe cases of COVID-19.

The article begins by outlining the pathophysiology of severe COVID-19 infection, emphasizing the hyperinflammatory response and cytokine storm that contribute to disease severity. Stem cell-based therapies offer promise in mitigating this inflammatory cascade by modulating the immune response and promoting tissue repair and regeneration.

One of the strengths of this review is its thorough examination of registered clinical trials investigating the efficacy and safety of stem cell therapies in COVID-19 management. By analyzing these trials, the authors provide valuable insights into the current landscape of stem cell research in the context of COVID-19, highlighting key findings, limitations, and future directions.

Furthermore, the review discusses various types of stem cells being explored for COVID-19 treatment, including mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and umbilical cord blood-derived stem cells. Each type of stem cell has unique properties and mechanisms of action, and the review elucidates how these cells may exert therapeutic effects in COVID-19.

Additionally, the safety profile of stem cell therapies is addressed, with an emphasis on potential adverse effects and strategies for minimizing risks. While stem cell therapy holds promise, it is essential to ensure that rigorous safety measures are in place to protect patients participating in clinical trials.

Overall, this narrative review provides a comprehensive overview of the current state of stem cell-based therapies for severe COVID-19 infection. By synthesizing existing evidence from registered clinical trials and discussing key considerations, the review serves as a valuable resource for researchers, clinicians, and policymakers involved in COVID-19 management and stem cell therapy development. However, it also underscores the need for further research to elucidate the optimal use of stem cell therapies in combating this global health crisis.

Rewiew english!